Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin D Litcofsky

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Nature Methods|October 9, 2012
Iterative plug-and-play methodology for constructing and modifying synthetic gene networksKevin D Litcofsky, Raffi B Afeyan, Russell J Krom, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2023
Impact of a Purified Microbiome Therapeutic on Abundance of Antimicrobial Resistance Genes in Patients With Recurrent Clostridioides difficile InfectionTimothy J Straub, Mary-Jane Lombardo, Jessica A Bryant, et al.
The Journal of Infectious Diseases|August 2, 2025
Comparability of gastrointestinal microbiome and bile acid profiles in patients with first or multiply recurrent Clostridioides difficile infectionJessica A Bryant, Timothy J Straub, Darrell S Pardi, et al.
Nature Medicine|January 6, 2026
The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiomeJessica A Bryant, Marin Vulić, Emily A Walsh, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 8, 2020
SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 TrialBarbara H McGovern, Christopher B Ford, Matthew R Henn, et al.
The New England Journal of Medicine|January 19, 2022
SER-109, an Oral Microbiome Therapy for Recurrent <i>Clostridioides difficile</i> InfectionPaul Feuerstadt, Thomas J Louie, Bret Lashner, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Nature Methods|October 9, 2012
Iterative plug-and-play methodology for constructing and modifying synthetic gene networksKevin D Litcofsky, Raffi B Afeyan, Russell J Krom, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2023
Impact of a Purified Microbiome Therapeutic on Abundance of Antimicrobial Resistance Genes in Patients With Recurrent Clostridioides difficile InfectionTimothy J Straub, Mary-Jane Lombardo, Jessica A Bryant, et al.
The Journal of Infectious Diseases|August 2, 2025
Comparability of gastrointestinal microbiome and bile acid profiles in patients with first or multiply recurrent Clostridioides difficile infectionJessica A Bryant, Timothy J Straub, Darrell S Pardi, et al.
Nature Medicine|January 6, 2026
The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiomeJessica A Bryant, Marin Vulić, Emily A Walsh, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 8, 2020
SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 TrialBarbara H McGovern, Christopher B Ford, Matthew R Henn, et al.
The New England Journal of Medicine|January 19, 2022
SER-109, an Oral Microbiome Therapy for Recurrent <i>Clostridioides difficile</i> InfectionPaul Feuerstadt, Thomas J Louie, Bret Lashner, et al.
Pageof 1